Immuno-monitoring reveals an extended subclinical disease activity in tocilizumab-treated giant cell arteritisAndrea D. Gloor(University Hospital of Bern), Peter M. Villiger(University of Bern)Lara D. VeekenMay 22, 201810.1093/rheumatology/key158Cited by 40SaveCiteExport RISWatch citationsRelated PapersSiglec-9 transduces apoptotic and nonapoptotic death signals into neutrophils depending on the proinflammatory cytokine environment|Blood|2005|216Magnetic resonance angiography in giant cell arteritis: results of a randomized controlled trial of tocilizumab in giant cell arteritis|Lara D. Veeken|2018|109